Fresenius stock JPMorgan keeps EUR 55.20 target, slightly lower pre-market
Published on 10/28/2026 at 07:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst view and trading agenda
- JPMorgan maintained its Overweight rating and a EUR 55.20 target for Fresenius on October 27, 2026.
- Fresenius is scheduled to publish third-quarter 2026 results on November 4, 2026.
- Fresenius stock trades pre-market at EUR 46.10 at 7:36 a.m. CET at Lang & Schwarz on October 28, 2026, 0.35 percent below the Xetra close of October 27, 2026.
On October 27, 2026, Börse Express reported that JPMorgan maintained its Overweight rating on Fresenius and kept its price target at EUR 55.20. Fresenius stock trades pre-market at EUR 46.10 at 7:36 a.m. CET at Lang & Schwarz on October 28, 2026, 0.35 percent below the Xetra close of October 27, 2026 (EUR 46.26).
Analyst view remains positive
The report said analyst David Adlington continued to view Fresenius favorably ahead of the company’s third-quarter results. JPMorgan’s revenue estimate was 1.60 percent above consensus, while its adjusted operating-profit view was in line with other analysts, according to Börse Express.
Ahead of the Xetra open
The pre-market indication is EUR 0.16 below the reference close. The further course from the Xetra open at 9:00 a.m. CET/CEST is shown by the continuously updated real-time quote of Fresenius stock.
Business and the next date
Fresenius operates hospitals and develops medicines and infusion solutions, according to its Investor Relations website. The company is scheduled to publish its third-quarter 2026 results on November 4, 2026, as listed by Fresenius. Market context: Market report DAX.
